# Biotech Daily Digest — 2026-01-28

**37 items from 3 sources**

## Summary by Source

- Endpoints News: 9 items
- Fierce Biotech: 9 items
- arXiv q-bio: 19 items


## Endpoints News

- **[Biopharma Sentiment Index | Q1 2026](https://endpoints.news/biopharma-sentiment-index-q1-2026/)**  
  _Wed, 28 Jan 2026 12:45:40 +0000_  
  The latest BPSI shows signs of a more durable phase in the biopharma recovery, with improvements across every metric.


 After four years of hunkering down, the mood in biopharma turned sharply more optimistic heading into ...

- **[Cellares raises $257M to fund global expansion as it eyes 2027 IPO](https://endpoints.news/cellares-raises-257m-to-fund-global-expansion-as-it-eyes-2027-ipo/)**  
  _Wed, 28 Jan 2026 12:00:48 +0000_  
  Clinical-stage cell therapy manufacturer Cellares has raised $257 million in a Series D round as it gears up commercially and prepares to go public.

 Cellares aims to launch its commercial cell therapy manufacturing services in ...

- **[Lilly partners with recombinase-based gene editing startup Seamless Therapeutics](https://endpoints.news/lilly-partners-with-startup-developing-recombinase-based-gene-editing/)**  
  _Wed, 28 Jan 2026 12:00:19 +0000_  
  Seamless Therapeutics, a startup developing a new form of gene editing based on enzymes called recombinases, has struck a partnership with Eli Lilly that could be worth more than $1.12 billion, the company announced Wednesday ...

- **[Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data](https://endpoints.news/boehringer-ingelheim-takes-rare-kidney-disease-drug-to-phase-3-despite-puzzling-mid-stage-data/)**  
  _Wed, 28 Jan 2026 11:59:20 +0000_  
  Boehringer Ingelheim’s experimental pill has shown signs of improving kidney function in patients with a rare renal condition in a mid-stage trial. But the data are somewhat confusing, with the lowest dose working better than ...

- **[Updated: CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations](https://endpoints.news/cms-picks-lillys-trulicity-for-third-round-of-medicare-negotiations/)**  
  _Tue, 27 Jan 2026 22:26:48 +0000_  
  

- **[Cardiff execs depart as company drops mixed Phase 2 data](https://endpoints.news/cardiff-execs-depart-as-company-drops-mixed-phase-2-data/)**  
  _Tue, 27 Jan 2026 18:22:21 +0000_  
  Shares {$CRDF} of Cardiff Oncology fell more than 30% after the biotech disclosed mixed Phase 2 data and announced the departure of two of its top executives.

 San Diego-based Cardiff

- **[FDA lifts hold on one of two Phase 3 gene editing studies by Intellia](https://endpoints.news/fda-lifts-hold-on-one-of-two-phase-3-gene-editing-studies-by-intellia/)**  
  _Tue, 27 Jan 2026 15:52:33 +0000_  
  The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins.

 Intellia

- **[Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma](https://endpoints.news/insilicos-latest-deal-is-a-120m-cardiometabolic-drug-discovery-pact-with-qilu-pharma/)**  
  _Tue, 27 Jan 2026 15:40:01 +0000_  
  Insilico Medicine is having quite a month. Fresh from deals with Servier and Hygtia Therapeutics, the biotech has signed a new collaboration with Shanghai-based Qilu Pharmaceutical worth nearly  ...

- **[Updated: Roche’s obesity shot posts decent weight loss in mid-stage test, heads to Phase 3](https://endpoints.news/roches-obesity-shot-posts-decent-weight-loss-in-mid-stage-test-heads-to-phase-3/)**  
  _Tue, 27 Jan 2026 12:09:37 +0000_  
  Roche’s most advanced obesity drug allowed patients in a Phase 2 trial who took it for nearly a year to lose 18.3% of their weight after correcting for placebo, the Swiss pharma said Tuesday.  ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/calcimedica-stock-craters-calcium-channel-inhibitor-trial-stopped-over-safety-concern" hreflang="en">CalciMedica stock craters as calcium channel inhibitor trial stopped over 'safety concern'</a>](https://www.fiercebiotech.com/biotech/calcimedica-stock-craters-calcium-channel-inhibitor-trial-stopped-over-safety-concern)**  
  _Jan 28, 2026 8:09am_  
  CalciMedica’s stock nosedived after the biotech abandoned a phase 2 study of its calcium release-activated calcium channel inhibitor in patients with acute kidney injury over a “safety concern.”

- **[<a href="https://www.fiercebiotech.com/medtech/medtech-ma-rebounded-2025-softer-valuations-drive-competition-report" hreflang="en">Medtech M&amp;A 'rebounded' in 2025 as softer valuations drove deal competition: report</a>](https://www.fiercebiotech.com/medtech/medtech-ma-rebounded-2025-softer-valuations-drive-competition-report)**  
  _Jan 28, 2026 5:16am_  
  Bain & Company’s new 2026 global M&A report found that medtech dealmaking rebounded last year, with M&A players in 2026 seeking to “outperform the next-best owner” amid softer valuations for assets.

- **[<a href="https://www.fiercebiotech.com/biotech/lilly-pens-11b-pact-german-biotech-work-gene-editing-med-hearing-loss" hreflang="en">Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss</a>](https://www.fiercebiotech.com/biotech/lilly-pens-11b-pact-german-biotech-work-gene-editing-med-hearing-loss)**  
  _Jan 28, 2026 4:46am_  
  Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offerings by penning a pact with gene editing company Seamless Therapeutics.

- **[<a href="https://www.fiercebiotech.com/biotech/boehringer-channels-mid-stage-momentum-pivotal-kidney-disease-trial" hreflang="en">Boehringer channels midstage momentum into pivotal kidney disease trial</a>](https://www.fiercebiotech.com/biotech/boehringer-channels-mid-stage-momentum-pivotal-kidney-disease-trial)**  
  _Jan 28, 2026 5:40am_  
  Boehringer Ingelheim has shared more phase 2 data on its kidney disease candidate apecotrep, shedding light on the decision to start a pivotal trial of the prospect last week.

- **[<a href="https://www.fiercebiotech.com/biotech/200-jpm-pitches-novo-nordisk-bd-head-searches-next-metsera" hreflang="en">With 200 JPM meetings, Novo Nordisk BD head searches for the next Metsera </a>](https://www.fiercebiotech.com/biotech/200-jpm-pitches-novo-nordisk-bd-head-searches-next-metsera)**  
  _Jan 27, 2026 4:44pm_  
  If the pursuit of Metsera signaled Novo Nordisk was ready to pay top dollar for the right innovation, the aftermath has filled Tamara Darsow’s calendar with high-stakes screenings for new opportunities.

- **[<a href="https://www.fiercebiotech.com/medtech/td-cowen-picks-top-3-medtech-prospects-across-its-bones-bots-and-no-more-shots-portfolio" hreflang="en">TD Cowen picks top 3 medtech prospects across its ‘Bones, Bots, and No More Shots’ portfolio</a>](https://www.fiercebiotech.com/medtech/td-cowen-picks-top-3-medtech-prospects-across-its-bones-bots-and-no-more-shots-portfolio)**  
  _Jan 27, 2026 10:37am_  
  TD Cowen analysts Mathew Blackman and Drew Ranieri have named their top three medtech picks under their evolving “Bones, Bots and No More Shots” portfolio coverage.

- **[<a href="https://www.fiercebiotech.com/research/rethinking-heart-attacks-nervous-system-gone-haywire-leads-new-drug-targets" hreflang="en">Rethinking heart attacks as nervous system gone haywire sparks potential new drug targets</a>](https://www.fiercebiotech.com/research/rethinking-heart-attacks-nervous-system-gone-haywire-leads-new-drug-targets)**  
  _Jan 23, 2026 2:16pm_  
  Heart attacks are often thought of as a plumbing issue, the result of a blockage preventing blood from flowing through one of the heart’s major thoroughfares. But scientists studying the heart’s connection to the brain have devised a new model for the common injury, one where panicked neurons respond to the clogged ar…

- **[<a href="https://www.fiercebiotech.com/biotech/after-patient-death-fda-lifts-hold-one-2-late-stage-trials-testing-intellias-crispr-therapy" hreflang="en">After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia's CRISPR therapy</a>](https://www.fiercebiotech.com/biotech/after-patient-death-fda-lifts-hold-one-2-late-stage-trials-testing-intellias-crispr-therapy)**  
  _Jan 27, 2026 10:23am_  
  The FDA is freeing Intellia’s CRISPR therapy from one of two clinical holds, allowing a phase 3 study to resume after a grade 4 liver event and subsequent patient death was reported in the sister study.

- **[<a href="https://www.fiercebiotech.com/biotech/lisata-reclaims-china-rights-solid-tumor-candidate-ahead-acquisition" hreflang="en">Lisata reclaims China rights to solid tumor candidate ahead of acquisition</a>](https://www.fiercebiotech.com/biotech/lisata-reclaims-china-rights-solid-tumor-candidate-ahead-acquisition)**  
  _Jan 27, 2026 10:13am_  
  Ahead of its acquisition by cancer imaging company Kuva Labs, Lisata Therapeutics has regained the Chinese rights to its lead solid tumor candidate from Qilu Pharmaceutical.


## arXiv q-bio

- **[LabelKAN -- Kolmogorov-Arnold Networks for Inter-Label Learning: Avian Community Learning](https://arxiv.org/abs/2601.18818)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.18818v1 Announce Type: new 
Abstract: Global biodiversity loss is accelerating, prompting international efforts such as the Kunming-Montreal Global Biodiversity Framework (GBF) and the United Nations Sustainable Development Goals to direct resources toward halting species declines. A key challenge in achiev…

- **[Descriptive and risk analysis of vehicle movements linked to porcine reproductive and respiratory syndrome and porcine epidemic diarrhea transmission in US commercial swine farms](https://arxiv.org/abs/2601.18819)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.18819v1 Announce Type: new 
Abstract: Vehicle movements, including vehicle cabs and trailers, play a role in disseminating disease in swine production. However, there are many information gaps about vehicle movements patterns that increase the probability of disease transmission, which is crucial in develop…

- **[Schema-based active inference supports rapid generalization of experience and frontal cortical coding of abstract structure](https://arxiv.org/abs/2601.18946)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.18946v1 Announce Type: new 
Abstract: Schemas -- abstract relational structures that capture the commonalities across experiences -- are thought to underlie humans' and animals' ability to rapidly generalize knowledge, rebind new experiences to existing structures, and flexibly adapt behavior across context…

- **[Intrinsic Limits of Read Trimming in Single-Stranded Bisulfite Sequencing](https://arxiv.org/abs/2601.19002)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.19002v1 Announce Type: new 
Abstract: Single-stranded whole-genome bisulfite sequencing (ssWGBS) enables DNA methylation profiling in low-input and highly fragmented samples, including cell-free DNA, but introduces stochastic enzymatic artifacts that complicate preprocessing and downstream interpretation. I…

- **[Smooth embeddings in contracting recurrent networks driven by regular dynamics: A synthesis for neural representation](https://arxiv.org/abs/2601.19019)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.19019v1 Announce Type: new 
Abstract: Recurrent neural networks trained for time-series prediction often develop latent trajectories that preserve qualitative structure of the dynamical systems generating their inputs. Recent empirical work has documented topology-preserving latent organization in trained r…

- **[LvD: A New Algorithm for Computing the Likelihood of a Phylogeny](https://arxiv.org/abs/2601.19064)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.19064v1 Announce Type: new 
Abstract: There are few, if any, algorithms in statistical phylogenetics which are used more heavily than Felsenstein's 1973 pruning method for computing the likelihood of a tree. We present LvD, (Likelihood via Decomposition), an alternative to Felsenstein's algorithm based on a…

- **[Stroboscopic motion reversals in delay-coupled neural fields](https://arxiv.org/abs/2601.19125)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.19125v1 Announce Type: new 
Abstract: Visual illusions provide a window into the mechanisms underlying visual processing, and dynamical neural circuit models offer a natural framework for proposing and testing theories of their emergence. We propose and analyze a delay-coupled neural field model that explai…

- **[EnzyPGM: Pocket-conditioned Generative Model for Substrate-specific Enzyme Design](https://arxiv.org/abs/2601.19205)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.19205v1 Announce Type: new 
Abstract: Designing enzymes with substrate-binding pockets is a critical challenge in protein engineering, as catalytic activity depends on the precise interaction between pockets and substrates. Currently, generative models dominate functional protein design but cannot model poc…

- **[Long-term evolution of regulatory DNA sequences. Part 1: Simulations on global, biophysically-realistic genotype-phenotype maps](https://arxiv.org/abs/2601.19681)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.19681v1 Announce Type: new 
Abstract: Promoters and enhancers are cis-regulatory elements (CREs), DNA sequences that bind transcription factor (TF) proteins to up- or down-regulate target genes. Decades-long efforts yielded TF-DNA interaction models that predict how strongly an individual TF binds arbitrary…

- **[Hyperdisorder in tumor growth](https://arxiv.org/abs/2601.19852)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.19852v1 Announce Type: new 
Abstract: Tumor growth is constrained by spatial, mechanical, and metabolic factors whose alignment progressively breaks down across cellular, mesoscopic, and tissue scales as tumors expand. We hypothesize that this misalignment drives tumors toward a distinct architectural regim…

- **[Accelerating Large-Scale Cheminformatics Using a Byte-Offset Indexing Architecture for Terabyte-Scale Data Integration](https://arxiv.org/abs/2601.18921)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.18921v1 Announce Type: cross 
Abstract: The integration of large-scale chemical databases represents a critical bottleneck in modern cheminformatics research, particularly for machine learning applications requiring high-quality, multi-source validated datasets. This paper presents a case study of integrati…

- **[XIMP: Cross Graph Inter-Message Passing for Molecular Property Prediction](https://arxiv.org/abs/2601.19037)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.19037v1 Announce Type: cross 
Abstract: Accurate molecular property prediction is central to drug discovery, yet graph neural networks often underperform in data-scarce regimes and fail to surpass traditional fingerprints. We introduce cross-graph inter-message passing (XIMP), which performs message passing…

- **[GPCR-Filter: a deep learning framework for efficient and precise GPCR modulator discovery](https://arxiv.org/abs/2601.19149)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.19149v1 Announce Type: cross 
Abstract: G protein-coupled receptors (GPCRs) govern diverse physiological processes and are central to modern pharmacology. Yet discovering GPCR modulators remains challenging because receptor activation often arises from complex allosteric effects rather than direct binding a…

- **[GenPairX: A Hardware-Algorithm Co-Designed Accelerator for Paired-End Read Mapping](https://arxiv.org/abs/2601.19384)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.19384v1 Announce Type: cross 
Abstract: Genome sequencing has become a central focus in computational biology. A genome study typically begins with sequencing, which produces millions to billions of short DNA fragments known as reads. Read mapping aligns these reads to a reference genome. Read mapping for s…

- **[Decoding Cortical Microcircuits: A Generative Model for Latent Space Exploration and Controlled Synthesis](https://arxiv.org/abs/2506.11062)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2506.11062v2 Announce Type: replace 
Abstract: A central idea in understanding brains and building artificial intelligence is that structure determines function. Yet, how the brain's complex structure arises from a limited set of genetic instructions remains a key question. The ultra high-dimensional detail of n…

- **[Conservation priority mapping to prevent zoonotic spillovers](https://arxiv.org/abs/2601.13349)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2601.13349v2 Announce Type: replace 
Abstract: Diseases originating from wildlife pose a significant threat to global health, causing human and economic losses each year. The transmission of disease from animals to humans occurs at the interface between humans, livestock, and wildlife reservoirs, influenced by a…

- **[Multi-omics network reconstruction with collaborative graphical lasso](https://arxiv.org/abs/2403.18602)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2403.18602v2 Announce Type: replace-cross 
Abstract: Motivation: In recent years, the availability of multi-omics data has increased substantially. Multi-omics data integration methods mainly aim to leverage different molecular layers to gain a complete molecular description of biological processes. An attractiv…

- **[General Binding Affinity Guidance for Diffusion Models in Structure-Based Drug Design](https://arxiv.org/abs/2406.16821)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2406.16821v2 Announce Type: replace-cross 
Abstract: Structure-based drug design (SBDD) aims to generate ligands that bind strongly and specifically to target protein pockets. Recent diffusion models have advanced SBDD by capturing the distributions of atomic positions and types, yet they often underemphasize bi…

- **[Noradrenergic-inspired gain modulation attenuates the stability gap in joint training](https://arxiv.org/abs/2507.14056)**  
  _Wed, 28 Jan 2026 00:00:00 -0500_  
  arXiv:2507.14056v2 Announce Type: replace-cross 
Abstract: Recent work in continual learning has highlighted the stability gap -- a temporary performance drop on previously learned tasks when new ones are introduced. This phenomenon reflects a mismatch between rapid adaptation and strong retention at task boundaries,…
